A high-throughput platform for biophysical antibody developability assessment to enable AI/ML model training [PDF]
mAbsAntibodies must bind their targets with high affinity and specificity to achieve useful therapeutic activity. They must also possess suitable developability properties (e.g.
Ammar Arsiwala +27 more
doaj +2 more sources
Application of protein language models for antibody developability prediction [PDF]
mAbsProtein language models (PLMs) provide a powerful framework for learning sequence – property relationships in antibodies. However, their performance and reliability in real-world industrial antibody discovery pipelines remain underexplored.
Samad Amini +5 more
doaj +2 more sources
Characterising nanobody developability to improve therapeutic design using the Therapeutic Nanobody Profiler [PDF]
Communications BiologyDevelopability optimisation is an important step for successful biotherapeutic design. For monoclonal antibodies, developability is relatively well characterised. However, progress for novel biotherapeutics such as nanobodies is more limited. Differences
Gemma L. Gordon +3 more
doaj +2 more sources
Balancing the extremes for antibody developability: hydrophobic and electrostatic germline framework signatures for CDR-loop compensation [PDF]
mAbsAntibody therapeutics are a rapidly growing class of biopharmaceuticals, but concerns regarding potential developability issues persist. While complementarity-determining region (CDR) loops are imperative for antigen specificity and mutations are ...
Vera A. Spanke +9 more
doaj +2 more sources
Developability Evaluation of Single-Domain Antibody-Chelator Conjugates for Diagnostic Radiotracers [PDF]
AntibodiesBackground/Objectives: Developability assessment is a critical step in advancing antibody-based molecules toward clinical application. This evaluation typically begins during clinical candidate selection and continues throughout all modifications of the ...
Philipp D. Kaiser +5 more
doaj +2 more sources
MAbs, 2022 Therapeutic monoclonal antibodies and their derivatives are key components of clinical pipelines in the global biopharmaceutical industry. The availability of large datasets of antibody sequences, structures, and biophysical properties is increasingly ...
Rahul Khetan +2 more
exaly +2 more sources
Assessing developability early in the discovery process for novel biologics
MAbs, 2023 Beyond potency, a good developability profile is a key attribute of a biological drug. Selecting and screening for such attributes early in the drug development process can save resources and avoid costly late-stage failures.
Monica L Fernández-Quintero +2 more
exaly +3 more sources
Blueprint for antibody biologics developability
MAbs, 2023 Large-molecule antibody biologics have revolutionized medicine owing to their superior target specificity, pharmacokinetic and pharmacodynamic properties, safety and toxicity profiles, and amenability to versatile engineering. In this review, we focus on
Carl Mieczkowski +8 more
exaly +3 more sources
PROPERMAB: an integrative framework for in silico prediction of antibody developability using machine learning [PDF]
mAbsSelection of lead therapeutic molecules is often driven predominantly by pharmacological efficacy and safety. Candidate developability, such as biophysical properties that affect the formulation of the molecule into a product, is usually evaluated only ...
Bian Li +9 more
doaj +2 more sources
Developability considerations for bispecific and multispecific antibodies
MAbsBispecific antibodies (bsAb) and multispecific antibodies (msAb) encompass a diverse variety of formats that can concurrently bind multiple epitopes, unlocking mechanisms to address previously difficult-to-treat or incurable diseases. Early assessment of
Alaa Amash +9 more
exaly +3 more sources